Rigel Pharmaceuticals, Inc. (RIGL)
47.24
-0.04
(-0.08%)
USD |
NASDAQ |
Sep 11, 16:00
47.26
+0.02
(+0.04%)
Pre-Market: 20:00
Rigel Pharmaceuticals Enterprise Value : 825.83M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 825.83M |
| September 10, 2026 | 826.58M |
| September 09, 2026 | 825.46M |
| September 08, 2026 | 828.26M |
| September 04, 2026 | 852.51M |
| September 03, 2026 | 849.34M |
| September 02, 2026 | 866.50M |
| September 01, 2026 | 830.68M |
| August 31, 2026 | 806.06M |
| August 28, 2026 | 811.65M |
| August 27, 2026 | 818.74M |
| August 26, 2026 | 811.65M |
| August 25, 2026 | 816.69M |
| August 24, 2026 | 786.10M |
| August 21, 2026 | 800.65M |
| August 20, 2026 | 788.71M |
| August 19, 2026 | 820.61M |
| August 18, 2026 | 758.30M |
| August 17, 2026 | 736.48M |
| August 14, 2026 | 738.90M |
| August 13, 2026 | 705.51M |
| August 12, 2026 | 725.66M |
| August 11, 2026 | 728.46M |
| August 10, 2026 | 721.74M |
| August 07, 2026 | 693.95M |
| Date | Value |
|---|---|
| August 06, 2026 | 676.23M |
| August 05, 2026 | 699.73M |
| August 04, 2026 | 666.53M |
| August 03, 2026 | 642.84M |
| July 31, 2026 | 631.27M |
| July 30, 2026 | 654.59M |
| July 29, 2026 | 673.43M |
| July 28, 2026 | 662.80M |
| July 27, 2026 | 642.09M |
| July 24, 2026 | 629.97M |
| July 23, 2026 | 631.46M |
| July 22, 2026 | 649.74M |
| July 21, 2026 | 677.91M |
| July 20, 2026 | 684.62M |
| July 17, 2026 | 700.85M |
| July 16, 2026 | 721.93M |
| July 15, 2026 | 712.79M |
| July 14, 2026 | 712.60M |
| July 13, 2026 | 715.03M |
| July 10, 2026 | 738.34M |
| July 09, 2026 | 760.92M |
| July 08, 2026 | 745.43M |
| July 07, 2026 | 738.53M |
| July 06, 2026 | 695.53M |
| July 02, 2026 | 666.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 991.92M |
| Cytokinetics, Inc. | 10.34B |
| Perspective Therapeutics, Inc. | 87.67M |
| Capricor Therapeutics, Inc. | 339.48M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.29M |
| Revenue (Quarterly) | 78.70M |
| Total Expenses (Quarterly) | 61.41M |
| EPS Diluted (Quarterly) | 0.8835 |
| Gross Profit Margin (Quarterly) | 89.17% |
| Profit Margin (Quarterly) | 21.97% |
| Earnings Yield | 34.55% |
| Operating Earnings Yield | 9.42% |
| Normalized Earnings Yield | 34.57 |